Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) VP Robert E. Waltermire sold 442 shares of the business's stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $273.41, for a total value of $120,847.22. Following the completion of the sale, the vice president now owns 5,058 shares of the company's stock, valued at $1,382,907.78. The trade was a 8.04 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.
Madrigal Pharmaceuticals Stock Up 7.6 %
Shares of MDGL traded up $20.85 during mid-day trading on Friday, hitting $293.64. 864,385 shares of the company traded hands, compared to its average volume of 489,589. The company has a market capitalization of $6.40 billion, a PE ratio of -11.71 and a beta of -0.36. The company has a quick ratio of 5.93, a current ratio of 5.98 and a debt-to-equity ratio of 0.15. The business has a 50 day moving average of $315.33 and a 200 day moving average of $272.58. Madrigal Pharmaceuticals, Inc. has a 1-year low of $168.25 and a 1-year high of $368.29.
Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($4.92) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($6.94) by $2.02. The company had revenue of $62.18 million during the quarter, compared to analysts' expectations of $34.60 million. During the same period in the prior year, the business posted ($5.34) EPS. Equities research analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -23.77 EPS for the current year.
Hedge Funds Weigh In On Madrigal Pharmaceuticals
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC grew its stake in Madrigal Pharmaceuticals by 47.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 211 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 68 shares during the last quarter. Quest Partners LLC boosted its position in Madrigal Pharmaceuticals by 5,225.0% in the second quarter. Quest Partners LLC now owns 213 shares of the biopharmaceutical company's stock valued at $60,000 after buying an additional 209 shares during the last quarter. Centaurus Financial Inc. purchased a new stake in Madrigal Pharmaceuticals in the second quarter valued at approximately $163,000. Amalgamated Bank increased its holdings in Madrigal Pharmaceuticals by 20.2% in the 2nd quarter. Amalgamated Bank now owns 607 shares of the biopharmaceutical company's stock worth $170,000 after buying an additional 102 shares during the period. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in Madrigal Pharmaceuticals during the 2nd quarter worth approximately $204,000. Hedge funds and other institutional investors own 98.50% of the company's stock.
Analysts Set New Price Targets
A number of brokerages have weighed in on MDGL. StockNews.com raised Madrigal Pharmaceuticals to a "sell" rating in a research report on Saturday, October 12th. Cantor Fitzgerald restated a "neutral" rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday, November 20th. Oppenheimer dropped their target price on shares of Madrigal Pharmaceuticals from $375.00 to $350.00 and set an "outperform" rating on the stock in a report on Wednesday, October 23rd. HC Wainwright boosted their price target on shares of Madrigal Pharmaceuticals from $390.00 to $400.00 and gave the company a "buy" rating in a report on Tuesday. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $427.00 price target on shares of Madrigal Pharmaceuticals in a research report on Friday, January 10th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $351.67.
Check Out Our Latest Stock Analysis on MDGL
Madrigal Pharmaceuticals Company Profile
(
Get Free Report)
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Madrigal Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Madrigal Pharmaceuticals wasn't on the list.
While Madrigal Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
